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Summary
African animal trypanosomosis is arguably the most important animal disease impairing livestock agricultural development in sub-Saharan
Africa. In addition to vector control, the use of trypanocidal drugs is important in controlling the impact of the disease on animal health and production in most sub-Saharan countries. However, there are no internationally agreed standards (pharmacopoeia-type monographs or documented product specifications) for the quality control of these compounds. This means that it is impossible to establish independent quality control and quality assurance standards for these agents. An Monographs on diminazene aceturate (synonym: diminazene diaceturate), isometamidium chloride hydrochloride, homidium chloride and bromide salts and their relevant veterinary formulations for these agents are given in the annex to this paper. However, the authors do not recommend use of homidium bromide and chloride,
Introduction
Animal trypanosomosis, caused by trypanosomes of several species belonging to the genus Trypanosoma, is present in South America, Africa and part of Asia and affects a wide range of vertebrate animals.
In sub-Saharan African countries, African animal trypanosomosis (AAT) is one of the most important animal diseases, with 50 million cattle exposed to the bites of infective tsetse flies (Trypanosoma congolense, T. brucei brucei) or to infective tsetse flies and biting flies (T. vivax) (1) . In these zones, T. congolense, T. vivax and T. brucei brucei are the main pathogenic species encountered. The degree of disease severity in domestic ruminants depends on the species of the infecting trypanosomes, with T. congolense having a more severe impact than T. vivax and T. brucei on animal health and production (2) . Nevertheless, trypanosomosis is generally recognised as a serious disease that may be fatal if untreated. This is particularly true in susceptible animals such as zebu cattle (3) but also in trypanotolerant animals such as N'Dama cattle, which may suffer from pathological stress caused by trypanosomosis, as manifested by development of anaemia and reduced growth (3, 4, 5) .
The Food and Agriculture Organization of the United Nations (FAO) estimates that more than three million cattle die of trypanosomosis every year (6); in addition, there are significant indirect losses in the livestock sector as a consequence of abortion, infertility, weight loss, reduced draught power and reduced milk production (7) , all of which have an impact on people's livelihoods as well as on animal welfare.
Treatment with trypanocidal drugs of proven quality, administered intramuscularly and at the recommended dosage, reduces both the No. 12092014-00040-EN 4/42 direct and indirect losses caused by trypanosome infections in susceptible and in tolerant cattle (3, 5) . Direct annual losses from AAT are currently some US$1.5 billion and, overall, have the effect of limiting Africa's agricultural income to approximately US$4.5 billion a year below its potential level (8). The financial benefit of controlling this disease has been calculated to range from below US$500 per km 2 to well over US$5,000 per km 2 (9) . Given the importance of the livestock sector in sub-Saharan Africa, the consequence of AAT is that the lives of millions of individuals, families and rural communities who rely on cattle for their livelihood are devastated.
Apart from vector control, chemotherapy with trypanocidal drugs (also called trypanocides) is the most widely used method to combat AAT in most of sub-Saharan Africa. Internationally agreed standards for trypanocides, either as documented product specifications or as pharmacopoeia-type monographs, are lacking in the public domain, making quality control (QC) and compliance in the use of veterinary trypanocides in sub-Saharan Africa difficult and impossible to regulate.
Trypanocidal drugs in sub-Saharan Africa
Chemotherapy of AAT is undertaken using veterinary formulations that contain one of the currently available trypanocides. At present, only three compounds belonging to two chemical classes are widely available to treat trypanosomosis: diminazene diaceturate, belonging to the class of aromatic diamidines, and isometamidium chloride hydrochloride and homidium (chloride and bromide salts), which belong to the phenanthridinium class of trypanocidal agents.
Diminazene diaceturate is indicated in the treatment of cattle trypanosomosis, whereas the phenanthridinium class of compounds is used for both treatment and prevention. Isometamidium chloride hydrochloride is mainly used as a prophylactic drug (10) .
Homidium chloride and bromide are known to have mutagenic activity after metabolic activation in Salmonella Typhimurium in vitro (11) . This activity has been confirmed in some in vivo systems but not in others (12). Additional studies indicate that homidium bromide can
No. 12092014-00040-EN 5/42 be toxic at high concentrations (13). Nevertheless, the antiparasitic activity of homidium has been shown, and veterinary products containing homidium salts are registered and used in some African countries. For comprehensiveness and clarity of information, pharmacopoeia-type monographs on homidium salts are therefore included in the annex to this paper. However, the authors recommend that use of homidium salts for prevention and treatment of trypanosomosis should be actively discouraged and replaced with agents with a more favourable toxicity profile (10).
The trypanocidal products described in the annex have been on the market for several decades and parasite resistance to all three available trypanocides is increasing (14, 15 Unfortunately, the abundance of poor-quality products, together with their incorrect usage, inappropriate storage, incorrect estimation of the weight of animals to be treated and use of contaminated syringes, can lead to under-dosage and treatment failure and contribute to resistance in trypanosome populations. In addition, the failure to use sanative pairs of drugs (i.e. use of only one trypanocidal drug instead of two)
can lead to treatment failure and emergence and spread of parasiteresistant strains (10, 13, 15) . It is therefore necessary that quality trypanocides be stored and administered correctly (10 In tsetse-infested areas/countries of the sub-Sahara, trypanocidal drugs represent 40% to 50% of the total animal health market, providing a large and attractive target for the sale of sub-standard or counterfeit products (Merial, unpublished report).
The findings of market surveys and studies (19, 20, 21) on the quality of trypanocidal pharmaceutical formulations sold in markets in sub-Saharan Africa have shown that a substantial proportion were either registered products of poor quality, or were counterfeit products of poor quality or contained no active substance to treat trypanosomosis.
In particular, market surveys in Benin, Cameroon, Chad, Mali, Mauritania, Senegal and Togo showed that more than 40% (range 43% to 93%) of the ivermectin, diminazene, oxytetracycline and albendazole formulations analysed were of sub-standard quality or counterfeit (22, 23, 24). Very limited published information is available regarding surveys on the quality of veterinary drugs in East Africa (25), but anecdotal evidence suggests that the situation is similar to that in western and Central Africa (21, 23, 24).
The use of sub-standard or counterfeit trypanocides has severe implications for animal health, public health and the local economy.
Ineffective treatment with sub-curative doses of these drugs increases the risk of emergence of drug resistance in trypanosome populations (14, 24) . Trypanocidal drug resistance in animals has now been reported in 17 African countries (21). Moreover, food safety is also compromised by allowing unspecified and potentially harmful chemicals and/or their residues to enter the food chain. Careful examination of the packaging of trypanocides for quality of the carton, printing, sealing and hologram, and the indicated shelf life may on occasion provide grounds to suspect that the drug is of poor quality.
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However, it is necessary to use standardised chemical analytical procedures to identify sub-standard or counterfeit drugs with certainty.
Currently there are no authoritative pharmacopoeia-type monographs or product specifications for these widely used trypanocidal drugs. 
International alliance for quality control of veterinary trypanocidal drugs

Conclusions
The problem of poor-quality and/or falsified or fake drugs is particularly pronounced in developing countries. Measure the areas of the peak responses in the chromatograms for solutions (a) and (b) and calculate the content of related substances as a percentage. In the chromatogram of solution (a), the area of any peak, other than the principal peaks, is not greater than that obtained with solution (a) (1.0%). The sum of the areas of all peaks, other than the principal peak, is not greater than twice the area of the principal peak obtained with solution (b) (2.0%). Disregard any peak with an area less than 0.05 times the area of the principal peak in the chromatogram of solution (b). The test is not valid unless the relative standard deviation of the retention time of the principal peak, in replicate injections for a system suitability test, is not greater than 2.0 and the resolution between adjacent peaks is not less than 1.5. Inject 20 μl each of solutions (a), (b) and (c). The run time should be 5 min longer than the principal peak obtained in the chromatogram of solution (c).
Assay
Identification of components.
Use the chromatogram supplied with isometamidium chloride hydrochloride RS for peak identification. Loss on drying: dry 1.0 g isometamidium chloride hydrochloride to constant weight at 105°C under reduced pressure; it loses not more than 8.0% w/w. Water: determine as described in Section 2.8 (Determination of water by the Karl Fischer method, Method A) in the International Pharmacopoeia 5 using 0.100 g of the substance; the water content is not more than 8.0% w/w. Identification of components. Use the chromatogram supplied with isometamidium chloride hydrochloride RS for peak identification. Description: dark red crystalline or amorphous powder.
Solubility: dissolve 1.0 g homidium bromide in water R and make up to 20 ml with the same solvent. Homidium bromide dissolves completely to give a red solution free from particulate matter.
Homidium bromide is also slightly soluble in chloroform R.
Category: trypanocidal agent.
Storage: store in a closed container excluding light and humidity.
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Requirements: homidium bromide contains not less than 98% and not more than the equivalent of 102% of C 21 H 20 N 3 Br calculated with reference to the dried substance.
Identity tests: either A and C or B and C may be used.
A. Carry out the examination as described in Section 1.7
(Spectrophotometry in the infrared region) in the International calculate the related substances as a percentage. In the chromatogram for solution (a), the area of any peak, other than the principal peak, is not greater than that obtained with solution (b). The sum of the areas of all peaks, other than the principal peak, is not greater than twice the area of that obtained with solution (b). Disregard any peak with an area less than 0.1% of the principal peak in the chromatogram Inject 20 μl each of solutions (a) and (b) and allow 10 min analysis time for each sample. Measure the areas of the peak responses obtained in the chromatograms from solutions (a) and (b) and calculate the related substances as a percentage. In the chromatogram of solution (a), the area of any peak, other than the principal peak, is not greater than that obtained with solution (b). The sum of the areas of all peaks, other than the principal peak, is not greater than twice the area of that obtained with solution (b). Disregard any peak with an area less than 0.1% of the principal peak in the chromatogram of solution (b). The test is not valid unless the relative standard deviation of the retention time of the principal peak is not greater than 1.0.
Assay: carry out the test as described in Section 1.14.4 (Highperformance liquid chromatography) in the International Storage: store in a closed container excluding light and humidity.
Requirements: complies with the general monograph regarding tablets in the International Pharmacopoeia 12 . Homidium chloride tablets contain not less than 90.0% and not more than 110.0% of the amount of C 21 H 20 N 3 Cl.C 2 H 5 OH stated on the label.
Labelling: the designation homidium chloride tablets for injection indicates that the substance complies with the general monographs regarding tablets 12 , and parenteral preparations 8 in the International Pharmacopoeia and may be used for intramuscular administration.
Expiry date.
Additional information: homidium chloride tablets contain a mixture of homidium chloride ethanolate (C 21 H 20 N 3 Cl.C 2 H 5 OH). Uniformity of mass: carry out the examination as described in Section 5.2 (Uniformity of mass for single-dose preparations) in the International Pharmacopoeia 14 . Not more than 2 of 20 individual masses deviate from average mass by more than 5% and none deviates by more than 10%. If film-coated tablets fail this test it may be because of variability in the thickness (mass) of the coatings. In such a 
Identity tests: Either
